An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that
will enroll approximately 100 adult outpatients in Canada who have received a positive
SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1)
to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11
days) or usual care. Blood samples will be collected to determine if icosapent ethyl use
lowers circulating pro-inflammatory biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Medical and Surgical Knowledge Translation Research Group